Leukocytoclastic vasculitis due to etanercept.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10955351.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recently etanercept, a soluble recombinant tumor necrosis factor receptor:Fc fusion protein, became available to treat patients with rheumatoid arthritis (RA). Among adverse reactions are cutaneous side effects, which occur in about 5% of patients. These have included mostly injection site reactions as well as urticarial reactions. We describe the first case of leukocytoclastic vasculitis associated with the use of etanercept in a patient with severe, deforming RA previously unresponsive to multiple therapies. Discontinuation of the drug led to complete resolution of the vasculitis.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Immunoglobulin G
- Recombinant Proteins
- Vasculitis, Leukocytoclastic, Cutaneous